Amer Renal Assoc Stock Fundamentals
Amer Renal Assoc fundamentals help investors to digest information that contributes to Amer Renal's financial success or failures. It also enables traders to predict the movement of Amer Stock. The fundamental analysis module provides a way to measure Amer Renal's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Amer Renal stock.
Amer |
Amer Renal Assoc Company Current Valuation Analysis
Amer Renal's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Amer Renal Current Valuation | 1.26 B |
Most of Amer Renal's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Amer Renal Assoc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Amer Renal Assoc has a Current Valuation of 1.26 B. This is 91.23% lower than that of the Healthcare sector and 83.84% lower than that of the Diagnostics & Research industry. The current valuation for all United States stocks is 92.42% higher than that of the company.
Amer Renal Assoc Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Amer Renal's current stock value. Our valuation model uses many indicators to compare Amer Renal value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Amer Renal competition to find correlations between indicators driving Amer Renal's intrinsic value. More Info.Amer Renal Assoc is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.25 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Amer Renal Assoc is roughly 4.03 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Amer Renal's earnings, one of the primary drivers of an investment's value.Amer Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Amer Renal's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Amer Renal could also be used in its relative valuation, which is a method of valuing Amer Renal by comparing valuation metrics of similar companies.Amer Renal is currently under evaluation in current valuation category among its peers.
Amer Fundamentals
| Return On Equity | 17.51 | |||
| Return On Asset | 4.35 | |||
| Profit Margin | (1.11) % | |||
| Operating Margin | 9.73 % | |||
| Current Valuation | 1.26 B | |||
| Shares Outstanding | 34.54 M | |||
| Shares Owned By Insiders | 9.15 % | |||
| Shares Owned By Institutions | 80.77 % | |||
| Number Of Shares Shorted | 608.63 K | |||
| Price To Earning | 144.04 X | |||
| Price To Book | (20.05) X | |||
| Price To Sales | 0.49 X | |||
| Revenue | 814.1 M | |||
| Gross Profit | 254.5 M | |||
| EBITDA | 113.52 M | |||
| Net Income | (16.86 M) | |||
| Cash And Equivalents | 126.9 M | |||
| Cash Per Share | 3.68 X | |||
| Total Debt | 724.51 M | |||
| Debt To Equity | 3.94 % | |||
| Current Ratio | 1.05 X | |||
| Book Value Per Share | (2.33) X | |||
| Cash Flow From Operations | 174.15 M | |||
| Short Ratio | 3.91 X | |||
| Earnings Per Share | (0.52) X | |||
| Price To Earnings To Growth | 2.41 X | |||
| Number Of Employees | 4.98 K | |||
| Beta | 1.11 | |||
| Market Capitalization | 397.94 M | |||
| Total Asset | 938.28 M | |||
| Retained Earnings | (192.31 M) | |||
| Working Capital | 96.27 M | |||
| Current Asset | 193.75 M | |||
| Current Liabilities | 97.47 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Other Consideration for investing in Amer Stock
If you are still planning to invest in Amer Renal Assoc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Amer Renal's history and understand the potential risks before investing.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |